Oxford Biomedica (LON:OXB) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Shares of Oxford Biomedica plc (LON:OXB) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 664.67 and traded as low as GBX 600. Oxford Biomedica shares last traded at GBX 603.19, with a volume of 228,335 shares changing hands.

Analysts Set New Price Targets

OXB has been the topic of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Royal Bank Of Canada cut their price target on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research note on Wednesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Oxford Biomedica has a consensus rating of “Buy” and a consensus price target of GBX 633.38.

Oxford Biomedica Price Performance

The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. The company has a market cap of £726.22 million, a price-to-earnings ratio of -22.29 and a beta of 1.12. The company has a fifty day simple moving average of GBX 615.15 and a two-hundred day simple moving average of GBX 664.67.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.